GlassScriptPhysician profile
Orion Seth Nelson
NPI 1508401670
$3,295.69
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $1,141 · 2023: $1,480 · 2024: $20.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.21 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $328.29 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $306.46 | 2022-2023 | |
| Glaxosmithkline, LLC. | $295.01 | 2022-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $277.99 | 2021-2024 | |
| Lilly USA, LLC | $210.00 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $145.80 | 2022-2023 | |
| Antares Pharma, INC. | $105.40 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $103.11 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $93.08 | 2021-2023 | Xarelto, Spravato |
| Supernus Pharmaceuticals, INC. | $83.38 | 2022-2023 | Qelbree, Xyosted |
| Astellas Pharma US INC | $81.30 | 2021-2023 | Myrbetriq, Veozah |
| Kowa Pharmaceuticals America, INC. | $60.42 | 2022-2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals LP | $58.20 | 2022-2023 | Farxiga, Airsupra |
| Alexion Pharmaceuticals, INC. | $55.04 | 2023 | Strensiq |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orion Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.